vs
Side-by-side financial comparison of Adagene Inc. (ADAG) and Biogen (BIIB). Click either name above to swap in a different company.
Adagene Inc. is a global clinical-stage biotechnology company specializing in the research, development, and commercialization of innovative antibody-based cancer immunotherapies. Leveraging its proprietary next-generation antibody technology platforms, it develops targeted oncology treatments for patients across global markets, with core R&D bases in China and clinical programs covering North America, Asia, and Europe.
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for ...
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.6B | ||
| Q1 25 | — | $2.4B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.5B | ||
| Q1 24 | — | $2.3B |
| Q4 25 | — | $-48.9M | ||
| Q3 25 | — | $466.5M | ||
| Q2 25 | — | $634.8M | ||
| Q1 25 | — | $240.5M | ||
| Q4 24 | — | $266.7M | ||
| Q3 24 | — | $388.5M | ||
| Q2 24 | — | $583.6M | ||
| Q1 24 | — | $393.4M |
| Q4 25 | — | 78.3% | ||
| Q3 25 | — | 73.4% | ||
| Q2 25 | — | 77.1% | ||
| Q1 25 | — | 74.1% | ||
| Q4 24 | — | 76.2% | ||
| Q3 24 | — | 74.1% | ||
| Q2 24 | — | 77.8% | ||
| Q1 24 | — | 76.3% |
| Q4 25 | — | -2.5% | ||
| Q3 25 | — | 22.0% | ||
| Q2 25 | — | 28.1% | ||
| Q1 25 | — | 12.8% | ||
| Q4 24 | — | 11.9% | ||
| Q3 24 | — | 18.3% | ||
| Q2 24 | — | 28.3% | ||
| Q1 24 | — | 20.3% |
| Q4 25 | — | -2.1% | ||
| Q3 25 | — | 18.4% | ||
| Q2 25 | — | 24.0% | ||
| Q1 25 | — | 9.9% | ||
| Q4 24 | — | 10.9% | ||
| Q3 24 | — | 15.8% | ||
| Q2 24 | — | 23.7% | ||
| Q1 24 | — | 17.2% |
| Q4 25 | — | $-0.35 | ||
| Q3 25 | — | $3.17 | ||
| Q2 25 | — | $4.33 | ||
| Q1 25 | — | $1.64 | ||
| Q4 24 | — | $1.82 | ||
| Q3 24 | — | $2.66 | ||
| Q2 24 | — | $4.00 | ||
| Q1 24 | — | $2.70 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
